NR1H4 and Hepatic steatosis: In the gut, FXR promotes the expression of fibroblast growth factors FGF15/19, and further activates fibroblast growth factor receptor 4 (FGFR4) and β-klotho in hepatocytes, thereby inhibiting bile acid synthesis and reducing hepatic steatosis and insulin resistance (33, 34).